By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...